Heather Getz
MYOMOAbout Heather C. Getz
Independent director (Class II) at Myomo (MYO), age 50 as of April 14, 2025; first appointed March 2024 and nominated for a new three-year term through the 2028 annual meeting. A seasoned healthcare/medtech finance operator, she is Chief Financial and Operations Officer and Corporate Secretary of Butterfly Network (NYSE: BFLY), a CPA, and an Audit Committee Financial Expert. Education: B.S. in Accountancy and MBA, both from Villanova University; member of NACD.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| BioTelemetry, Inc. | Chief Financial & Administrative Officer; CFO; VP Finance | 2009–2021 | Led finance, accounting, RCM; helped grow market cap from ~$50M to $2.8B at 2021 sale to Philips (PHG) |
| Healthy.io Ltd. | CFO; President North America | Nov 2021–Apr 2022 | Senior leadership at private medtech; finance and operating scope |
| Alita Pharmaceuticals; VIASYS Healthcare; Sunoco, Inc. | Various leadership roles | Prior to 2009 | Progressively senior finance/ops experience |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Butterfly Network, Inc. (NYSE: BFLY) | Chief Financial & Operations Officer; Corporate Secretary; previously CFO | CFO since May 2022; CFO/COO since Jul 2023 (current) | Public company executive; finance and operations leadership |
| Vital Connect, Inc. | Director; Chair of Audit Committee; previously Lead Independent Director | Director/Audit Chair (current); Lead Independent Director Apr 2022–Oct 2023 | Audit leadership; independent oversight at private medtech |
Board Governance
- Independence: Board determined Ms. Getz is independent under NYSE American rules; majority of MYO’s board is independent.
- Committees: Audit Committee Chair (financial expert designation); committee also includes T. F. Kirk, A. Knapp, T. A. Crowley.
- Board/classification: 7 directors in three staggered classes; Ms. Getz is Class II, nominated through 2028. Lead Independent Director: Thomas F. Kirk.
- Attendance: In 2024, each director attended at least 75% of board meetings (4 held). For committees (Audit 7; Comp 5; Nominating 4; Tech/Quality/Regulatory 6), all directors met 75% threshold in 2024 except Ms. Knapp on Nominating.
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Cash fees (2024 actual) | $43,750 | Fees earned or paid in cash for 2024 service (pro‑rated; joined Mar 2024) |
| Annual cash retainer (policy from Jun 2024) | $55,000 per year | Paid quarterly to non‑employee directors |
| Committee chair fee (policy from Jun 2024) | +$5,000 per year | Additional annual fee for committee chairs (Getz chairs Audit) |
Performance Compensation
| Grant date | Instrument | Shares/Units | Grant-date fair value | Vesting |
|---|---|---|---|---|
| Jun 5, 2024 | Restricted Stock Units (annual director grant) | 12,034 | $42,000 | Vests over 4 quarters beginning Sep 5, 2024 |
| Dec 31, 2024 (as of) | Unvested RSUs held | 6,017 | — | Outstanding balance as of year‑end 2024 (no options) |
Notes:
- Director equity is time-based (no explicit performance metrics).
Other Directorships & Interlocks
- Public company directorships: None disclosed. Current public company role is as an executive (not director) at Butterfly Network (BFLY).
- Private company board: Vital Connect (Director; Audit Chair; prior Lead Independent Director).
- Related-party transactions: The proxy discloses multiple financing participations by significant shareholders (AIGH, Rosalind, Triple Gate), but no transactions involving Ms. Getz or entities affiliated with her are identified.
- Section 16 compliance: The proxy notes certain late Form 4s for named executives; Ms. Getz is not listed among exceptions.
Expertise & Qualifications
- Audit Committee Financial Expert; deep finance/operations background in medtech; CPA; NACD member.
- Demonstrated value creation at BioTelemetry culminating in $2.8B sale to Philips in 2021.
- Education: B.S. Accountancy; MBA (Villanova University).
Equity Ownership
| Item | Detail |
|---|---|
| Total beneficial ownership (3/31/2025) | 9,026 shares; <1% of outstanding |
| RSUs excluded from 60‑day count | 3,008 unvested RSUs excluded from “beneficial” tally within 60 days (as of 3/31/2025) |
| Year‑end RSU balance (12/31/2024) | 6,017 unvested RSUs; no options outstanding |
| Pledging/Hedging | Company policy prohibits short sales/derivatives and pledging without prior approval; policy applies to directors. |
Governance Assessment
-
Strengths and signals
- Independent director and Audit Committee Chair with “financial expert” designation; strong alignment with MYO’s current growth and reimbursement-driven scaling needs.
- Attendance/engagement threshold met; Audit Committee active (7 meetings in 2024).
- Compensation mix emphasizes equity via quarterly‑vesting RSUs, aligning director pay with shareholder outcomes; modest cash retainer vs small-cap peers.
- No related‑party transactions involving Ms. Getz disclosed; MYO’s insider trading policy restricts hedging/pledging, supporting alignment.
-
Watch items
- Time commitments: dual role as BFLY CFO/COO and MYO Audit Chair implies a heavy workload; monitor ongoing attendance and committee throughput.
- Ownership is <1% given recent appointment; equity accumulation will depend on continued service and RSU vesting cadence.
-
RED FLAGS
- None specifically identified for Ms. Getz in the proxy: no attendance shortfalls, no related‑party transactions, no pledging disclosed, and no Section 16 exceptions noted for her.